Technology

Immunotherapy

Our main approaches to immunotherapy is therapeutic DNA vaccines

Therapeutic DNA Vaccine Technology: Immune Enhancing Technology

DNA therapeutic vaccine technology, a globally competitive platform technology, is one of Genexine’s core proprietary technologies. Therapeutic vaccine is prepared by introducing antigen gene and dendritic cell targeting gene into high-efficiency expression vector. When administered, it induces antigen-specific immune response and therefore works as ‘therapeutic vaccine’ against infectious diseases and cancer.

Genexine has a long experience in developing therapeutic vaccines since 1999 and continues to improve therapeutic vaccines by adopting DNA delivery technology (electroporation) to efficiently maximize target gene expression in human body. Our current DNA vaccine pipeline includes vaccines targeting human papilloma virus (HPV) type 16 and 18 associated cervical intraepithelial neoplasia (CIN) which eventually causes cervical cancer.

With Genexine’s experience and expertise, we will provide first-in-class DNA therapeutic vaccine and wish to resolve the unmet medical needs of patients who previously experienced unsatisfactory results with conventional treatments.

Key Advantages of DNA Vaccines

Design
  • More rapid design
  • DNA can be rapidly isolated and cloned
Production
  • Relatively inexpensive, reproducible, large-scale production
  • Proper protein folding for correct epitope expression
Safety
  • Unable to revert to a pathogenic form
    (unlike live-attenuated vaccines)
  • Good safety record in human studies
Convenience
  • Ease in improving or adapting plasmid sequence
  • Multiple vaccines can be given in one injection
  • Ease in formulating with adjuvants
Immune Responses
  • Ability to induce both humoral and cellular responses
Transport
  • Highly stable and no cold chain required

How Our DNA Vaccines Work

Publications

2014
  • Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. TJ Kim, HT Jin, SY Hur, HG Yang, YB Seo, SR Hong, CW Lee, SY Kim, JW Woo, KS Park, YY Hwang, JH Park, IH Lee, KT Lim, KH Lee, MS Jeong, CD Surh, YS Suh, JS Park and YC Sung. Nature Com. 2014, 5: 5317
2011
  • Dendritic cell internalization of α-galactosylceratmide from CD8 T cells induces potent antitumor CD8 T-cell responses. DH Choi, KS Kim, SH Yang, DH Chung, BY Song, J Sprent, JH Cho, YC Sung. Cancer Res. 2011, 71(24): 7442-7451
  • Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. KS Park, YB Seo, JY Lee, SJ Im, SH Seo, MS Song, YK Choi, YC Sung. Vaccine. 2011, 29(33): 5481-5487
2009
  • Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. SJ Im, SH Yang, SK Yoon and YC Sung. Immune network. 2009, 9(1): 20-26
  • Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. SH Seo, HT Jin, SH Park, JI Youn, YC Sung. Vaccine. 2009, 27(42): 5906-5912
  • Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Park KS, Lee J, Ahn SS, Byun YH, Seong BL, Baek YH, Song MS, Choi YK, Na YJ, Hwang I, YC Sung, Lee CG, Virology. 2009, 20;395(2): 182-189
2008
  • Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects. HT Jin, JI Youn, SY Choi, SH Seo, SH Park, MY Song, SH Yang and YC Sung. Cancer Gene Ther. 2008, 15(11): 693-702
  • Differential Regulation of Antigen-Specific CD8 + T cell Responses by IL-12p40 in a Dose-Dependent Manner. DJ Kim, Ji Youn, SH Seo, HT Jin and YC Sung. J Immunol. 2008, 180(11): 7167-7174